Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Clay Bunn

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Endocrinology|November 8, 2003
Regulation of insulin-like growth factor (IGF)-I action by matrix metalloproteinase-3 involves selective disruption of IGF-I/IGF-binding protein-3 complexesJohn L Fowlkes, Delila M Serra, R Clay Bunn, et al.
Bone|September 5, 2020
Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficitsKathryn M Thrailkill, R Clay Bunn, Sasidhar Uppuganti, et al.
Journal of Diabetes Research|June 26, 2014
Loss of insulin receptor in osteoprogenitor cells impairs structural strength of boneKathryn Thrailkill, R Clay Bunn, Charles Lumpkin, et al.
Bone|November 6, 2019
Constitutive activation of MEK1 in osteoprogenitors increases strength of bone despite impairing mineralizationJohn L Fowlkes, R Clay Bunn, Philip D Ray, et al.
Experimental Diabetes Research|July 13, 2011
Dysregulation of the intrarenal vitamin D endocytic pathway in a nephropathy-prone mouse model of type 1 diabetesJohn L Fowlkes, R Clay Bunn, Gael E Cockrell, et al.
Diabetes Care|April 16, 2009
Microalbuminuria in type 1 diabetes is associated with enhanced excretion of the endocytic multiligand receptors megalin and cubilinKathryn M Thrailkill, Teresa Nimmo, R Clay Bunn, et al.
Bone|December 20, 2016
The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetesKathryn M Thrailkill, Jeffry S Nyman, R Clay Bunn, et al.
Bone|January 29, 2020
Genetic ablation of SGLT2 function in mice impairs tissue mineral density but does not affect fracture resistance of boneKathryn M Thrailkill, R Clay Bunn, Sasidhar Uppuganti, et al.
Frontiers in Endocrinology|June 27, 2025
A myostatin inhibitory antibody combined with insulin, partially rescues the musculoskeletal phenotype of female insulin-deficient diabetic miceR Clay Bunn, Reuben Adatorwovor, Philip D Ray, et al.
Bone Reports|February 17, 2015
Effects of long-term doxycycline on bone quality and strength in diabetic male DBA/2J miceJohn L Fowlkes, Jeffry S Nyman, R Clay Bunn, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Endocrinology|November 8, 2003
Regulation of insulin-like growth factor (IGF)-I action by matrix metalloproteinase-3 involves selective disruption of IGF-I/IGF-binding protein-3 complexesJohn L Fowlkes, Delila M Serra, R Clay Bunn, et al.
Bone|September 5, 2020
Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficitsKathryn M Thrailkill, R Clay Bunn, Sasidhar Uppuganti, et al.
Journal of Diabetes Research|June 26, 2014
Loss of insulin receptor in osteoprogenitor cells impairs structural strength of boneKathryn Thrailkill, R Clay Bunn, Charles Lumpkin, et al.
Bone|November 6, 2019
Constitutive activation of MEK1 in osteoprogenitors increases strength of bone despite impairing mineralizationJohn L Fowlkes, R Clay Bunn, Philip D Ray, et al.
Experimental Diabetes Research|July 13, 2011
Dysregulation of the intrarenal vitamin D endocytic pathway in a nephropathy-prone mouse model of type 1 diabetesJohn L Fowlkes, R Clay Bunn, Gael E Cockrell, et al.
Diabetes Care|April 16, 2009
Microalbuminuria in type 1 diabetes is associated with enhanced excretion of the endocytic multiligand receptors megalin and cubilinKathryn M Thrailkill, Teresa Nimmo, R Clay Bunn, et al.
Bone|December 20, 2016
The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetesKathryn M Thrailkill, Jeffry S Nyman, R Clay Bunn, et al.
Bone|January 29, 2020
Genetic ablation of SGLT2 function in mice impairs tissue mineral density but does not affect fracture resistance of boneKathryn M Thrailkill, R Clay Bunn, Sasidhar Uppuganti, et al.
Frontiers in Endocrinology|June 27, 2025
A myostatin inhibitory antibody combined with insulin, partially rescues the musculoskeletal phenotype of female insulin-deficient diabetic miceR Clay Bunn, Reuben Adatorwovor, Philip D Ray, et al.
Bone Reports|February 17, 2015
Effects of long-term doxycycline on bone quality and strength in diabetic male DBA/2J miceJohn L Fowlkes, Jeffry S Nyman, R Clay Bunn, et al.
Pageof 3